Learn about our AAV gene therapy clinical trials
While we help raise awareness of clinical research opportunities, enrolling physicians are responsible for screening potential patients and confirming their eligibility. Eligibility criteria, based on pre-determined requirements related to the disease and the patient’s medical history, are described in the ClinicalTrials.gov study postings. These criteria allow us to conduct studies as safely as possible and control for health and disease factors that make it easier to compare results across subjects.
Participants may be ineligible if their immune systems have existing antibodies or neutralizing antibodies (NAbs) that will likely destroy the gene therapy before it can do its job. People who are treated with most gene therapies will develop NAbs, which currently prevent re-dosing with the gene. These are challenges that AskBio is actively working to overcome.
Clinical Trial: Congestive Heart Failure
We are actively enrolling patients with NYHA Class III heart failure to assess three doses of NAN-101. NAN-101 is a gene therapy that aims to activate protein phosphatase inhibitor 1 (I-1c) to inhibit the production of protein phosphatase 1 (PP1), a substance that plays an important role in the development of heart failure. The presence of I-1c has been shown to improve heart function in animal models of congestive heart failure (CHF).
NAN-101 is administered directly to the heart by catheterization in a process similar to coronary angioplasty, commonly used to deliver treatments such as stem cells to patients with heart disease.
The study’s primary objective is to assess the safety of NAN-101, as well as assess the impact of this treatment on patient health as measured by changes in exercise capacity, heart function, and other factors including quality of life.
Once AskBio publishes results from a controlled clinical trial that suggest the gene may provide benefit with acceptable safety for patients, we will open an expanded access study for that gene therapy.
Gene therapy clinical trials
Gene therapy clinical trial design varies depending on the disease, its prevalence and orphan disease classification, the type of therapy, and the number of participants. To bring these medicines to patients as efficiently and safely as possible, gene therapy trials often combine early- and late-phase processes and involve a small number of patients. At present, gene therapy is a one-time treatment. Individuals are dosed then followed for three to five years to assess the long-term safety and overall impact on their health.
In rare diseases, patients often do not live close to medical centers of excellence. As such, AskBio will help arrange and pay for their travel and design studies that allow for many assessments to occur at home.